US 11,779,692 B2
Peritoneal dialysis solution
Arduino Arduini, Arogno (CH); Mario Bonomini, Chieti (IT); Valentina Masola, Pernumia (IT); and Giovanni Gambaro, Scorzè (IT)
Assigned to COREQUEST Sagl, Lugano (CH)
Filed by COREQUEST Sagl, Lugano (CH)
Filed on May 12, 2021, as Appl. No. 17/318,001.
Claims priority of provisional application 63/026,936, filed on May 19, 2020.
Claims priority of application No. 20175357 (EP), filed on May 19, 2020.
Prior Publication US 2021/0361844 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 1/28 (2006.01); A61P 7/08 (2006.01); A61K 31/047 (2006.01); A61K 31/205 (2006.01); A61K 31/7004 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/40 (2006.01)
CPC A61M 1/287 (2013.01) [A61K 31/047 (2013.01); A61K 31/205 (2013.01); A61K 31/7004 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/40 (2013.01); A61P 7/08 (2018.01)] 29 Claims
 
1. A method for maintaining or restoring the removal of solutes and fluids in an individual in need thereof,
the method comprising: administering intraperitoneally (IP) to the individual in need thereof a peritoneal dialysis solution comprising:
(a) a lactate buffered solution comprising xylitol 1.5%, L-carnitine 0.02% and polydextrin 4.0%,
(b) a lactate buffered solution comprising glucose (1.5%), L-carnitine 0.02% and xylitol 2.0%,
(c) 0.7% Xylitol, 0.5% glucose e 0.02% carnitine, or
(d) 1.5% xylitol, 0.5% glucose, 0.02% carnitine,
wherein administering the peritoneal dialysis solution results in an improvement of the removal of solutes and fluids by the individual in need thereof,
and wherein the individual in need thereof has congestive heart failure resistant to diuretic therapy, and the congestive heart failure presents the following symptoms and clinical parameters:
(1) heart Failure with left ventricular ejection fraction ≤60% and heart Failure symptoms consistent with NYHA Classification of III-IV despite guidelines directed medical therapy (GDMT), or
(2) persistency of right ventricular failure due to after load mismatch as addressed by the presence of disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio >0.65 detected with right heart catheterization performed after stable GDMT and comprehensive of a loop diuretic drug at an oral dose of 2.0 mg/kg/day, coupled with urinary sodium excretion ≤65 m Eq/day, confirmatory of loop diuretic drug resistance.